Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
1.28
+0.04 (3.23%)
Real-time:   10:54AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.24 - 1.29
52 week 1.16 - 8.95
Open 1.24
Vol / Avg. 846,670.00/8.85M
Mkt cap 364.85M
P/E     -
Div/yield     -
EPS -1.12
Shares 271.25M
Beta 1.80
Inst. own 63%
Feb 27, 2017
Q4 2016 Novavax Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2016
Novavax Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 9, 2016
Q3 2016 Novavax Inc Earnings Call
Nov 9, 2016
Q3 2016 Novavax Inc Earnings Release
Sep 15, 2016
Novavax Inc to Discuss Topline RSVF Vaccine Data from Two Clinical Trials in Older Adults - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -2050.57% -432.93%
Operating margin -1959.39% -433.75%
EBITD margin - -414.72%
Return on average assets -53.98% -47.41%
Return on average equity -332.39% -60.10%
Employees 443 -
CDP Score - -

Address

20 Firstfield Rd
GAITHERSBURG, MD 20878-1760
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Officers and directors

James Francis Young Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 53
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. President, Research and Development
Age: 62
Bio & Compensation  - Reuters
John A. Herrmann III Senior Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Bob Darius Senior Vice President - Quality Operations
Bio & Compensation  - Reuters
Amy B. Fix Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Louis F. Fries III Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 56
Bio & Compensation  - Reuters
Iksung Cho Vice President - Biostatistics
Bio & Compensation  - Reuters